Clinical Trial Update: A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update indicating completion of a study evaluating Fresolimumab in patients with steroid-resistant primary focal segmental glomeruloscler…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Fresolimumab (Fresolimumab)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Primary Focal Segmental Glomerulosclerosis | Phase 2 | Status: COMPLETED